These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 19719730

  • 21. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V, Abraham G, Fathima N, Sundaram V, Reddy YN, Mathew M, Sathiah V.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 25. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 26. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B.
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D.
    Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM, Grinyó JM.
    Transplantation; 2001 Jun 15; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Modern approaches to combining sirolimus with calcineurin inhibitors.
    Stevens RB.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S21-4. PubMed ID: 19100901
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct 15; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.